Clinical and oncological outcomes in Chinese patients with renal cell carcinoma and venous tumor thrombus extension: single-center experience

World Journal of Surgical Oncology

Bin Wu¹  Xia Wang¹  Qiang Liu¹  Donghui Fu¹  Kefeng Wang¹  Zhenqun Xu¹  Shijie Li¹  Xiaonan Chen¹ 

[1] Department of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, People’s Republic of China

关键词: Prognostic factors;    Cancer-specific survival;    Venous tumor thrombus;    Renal cell carcinoma;   

Others  :  1146432
DOI  :  10.1186/s12957-015-0448-2

 received in 2014-05-21, accepted in 2015-01-08,  发布年份 2015

【 摘 要 】

Background

To evaluate the clinical and oncological outcomes and to identify prognostic factors for survival in Chinese patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT).

Methods

A total of 86 patients who underwent nephrectomy and tumor thrombectomy for RCC and venous tumor thrombus extension from 2003 to 2013 were included in this retrospective study. The records of these patients were reviewed. Kaplan-Meier analysis was used to determine cancer-specific survival (CSS). Prognostic factors for CSS were identified by univariate and multivariate analyses using the Cox proportional hazards regression mode.

Results

All patients in this cohort received radical nephrectomy and tumor thrombectomy. Median follow-up period was 27.0 months (range 3–111). No patients died intraoperatively, and the complication rate was 36.0%. The 1-, 3-, and 5-year CSS rates for all patients were 93.0%, 70.9%, and 58.1%, respectively, and those for patients without distant metastasis at presentation were 95.3%, 82.6%, and 68.6%, respectively. Multivariate Cox regression analysis showed that lymph node invasion, distant metastasis at presentation, and invasion of the inferior vena cava (IVC) wall were the independent prognostic factors for CSS in all patients. For patients without distant metastasis, tumor grade, lymph node invasion, and perinephric fat invasion were significantly associated with CSS on multivariate analysis.

Conclusions

Survival rates for patients with RCC and VTT were still poor. Our results indicated that lymph node invasion, distant metastasis at presentation, and invasion of the IVC wall were independent negative prognostic factors.

【 授权许可】

   
2015 Chen et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS. Contemporary management of renal tumors with venous tumor thrombus. J Urol. 2010; 184:833-41. quiz 1235
• [2]Kirkali Z, Van Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol. 2007; 52:658-62.
• [3]Cho MC, Kim JK, Moon KC, Kim HH, Kwak C. Prognostic factor for Korean patients with renal cell carcinoma and venous tumor thrombus extension: application of the new 2009 TNM staging system. Int Braz J Urol. 2013; 39:353-63.
• [4]Kaushik D, Linder BJ, Thompson RH, Eisenberg MS, Lohse CM, Cheville JC et al.. The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis. Urology. 2013; 82:136-41.
• [5]Sidana A, Goyal J, Aggarwal P, Verma P, Rodriguez R. Determinants of outcomes after resection of renal cell carcinoma with venous involvement. Int Urol Nephrol. 2012; 44:1671-9.
• [6]Martinez-Salamanca JI, Huang WC, Millan I, Bertini R, Bianco FJ, Carballido JA et al.. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol. 2011; 59:120-7.
• [7]Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nishikawa T, Nakano M et al.. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. Jpn J Clin Oncol. 2010; 40:1173-9.
• [8]Bigot P, Fardoun T, Bernhard JC, Xylinas E, Berger J, Roupret M et al.. Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful? World J Urol. 2014; 32:109-14.
• [9]Hirono M, Kobayashi M, Tsushima T, Obara W, Shinohara N, Ito K et al.. Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan. BMC Cancer. 2013; 13:447. BioMed Central Full Text
• [10]Tang Q, Song Y, Li XS, Zhang CJ, Cai L, Song G et al.. Surgical management and long-term outcomes of patients with renal cell carcinoma accompanied with venous tumor thrombus. Beijing Da Xue Xue Bao. 2013; 45:549-53.
• [11]Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al.. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649-55.
• [12]Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J et al.. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013; 37:1490-504.
• [13]Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension. Br J Urol. 1987; 59:390-5.
• [14]Abaza R. Robotic surgery and minimally invasive management of renal tumors with vena caval extension. Curr Opin Urol. 2011; 21:104-9.
• [15]Reese AC, Whitson JM, Meng MV. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol. 2013; 31:1305-9.
• [16]Hatakeyama S, Yoneyama T, Hamano I, Murasawa H, Narita T, Oikawa M et al.. Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center. BMC Urol. 2013; 13:47. BioMed Central Full Text
• [17]Swierzewski DJ, Swierzewski MJ, Libertino JA. Radical nephrectomy in patients with renal cell carcinoma with venous, vena caval, and atrial extension. Am J Surg. 1994; 168:205-9.
• [18]Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171:1071-6.
• [19]Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358:966-70.
• [20]Miyake H, Terakawa T, Furukawa J, Muramaki M, Fujisawa M. Prognostic significance of tumor extension into venous system in patients undergoing surgical treatment for renal cell carcinoma with venous tumor thrombus. Eur J Surg Oncol. 2012; 38:630-6.
• [21]Vergho DC, Loeser A, Kocot A, Spahn M, Riedmiller H. Tumor thrombus of inferior vena cava in patients with renal cell carcinoma – clinical and oncological outcome of 50 patients after surgery. BMC Res Notes. 2012; 5:5. BioMed Central Full Text
• [22]Whitson JM, Reese AC, Meng MV. Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus. Urol Oncol. 2013; 31:259-63.
• [23]Ali AS, Vasdev N, Shanmuganathan S, Paez E, Dark JH, Manas D et al.. The surgical management and prognosis of renal cell cancer with IVC tumor thrombus: 15-years of experience using a multi-specialty approach at a single UK referral center. Urol Oncol. 2013; 31:1298-304.
• [24]Kondo T, Ikezawa E, Takagi T, Kobayashi H, Hashimoto Y, Iizuka J et al.. Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: single-center experience. Int J Urol. 2013; 20:1072-7.
• [25]Tilki D, Nguyen HG, Dall’era MA, Bertini R, Carballido JA, Chromecki T et al.. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol. 2014; 66:577-83.
• [26]Ciancio G, Manoharan M, Katkoori D, De Los SR, Soloway MS. Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience. Eur Urol. 2010; 57:667-72.
• [27]Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004; 171:588-91.
• [28]Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol. 2004; 171:598-601.
• [29]Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED et al.. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer. 2005; 104:53-60.
• [30]Wagner B, Patard JJ, Mejean A, Bensalah K, Verhoest G, Zigeuner R et al.. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009; 55:452-9.
• [31]Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF et al.. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011; 59:912-8.